Sign In
Buy PCRX
$22.25
-0.710 (-3.09%)
At Close: Jun 02, 2026
/PRNewswire/ -- DOMA Perpetual Capital Management LLC (together with its affiliates, "DOMA"), which beneficially owns approximately 6.83% of the outstanding
Assenagon Asset Management S.A. Sells 250,594 Shares of Pacira BioSciences, Inc. $PCRX
03:16am, Monday, 22'nd Dec 2025
Assenagon Asset Management S.A. decreased its holdings in shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) by 51.9% in the undefined quarter, according to its most recent 13F filing with the SEC. The
5 Biotech Stocks to Watch for Potential Upside
03:21pm, Wednesday, 17'th Dec 2025
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and soli
PCRX's Iovera Outperforms RFA Therapy in Pilot Study for Low Back Pain
11:25am, Wednesday, 03'rd Dec 2025
Pacira BioSciences' iovera shows stronger, longer-lasting relief than RFA in a pilot CLBP study, highlighting its tissue-sparing approach and potential spine-care impact.
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Wednesday, 03'rd Dec 2025
BRISBANE, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of pati
Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical
04:01pm, Wednesday, 26'th Nov 2025
-- Lawsuit triggers 30-month stay under the Hatch Waxman Act -- BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to de
Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives $33.00 Average PT from Analysts
02:34am, Tuesday, 18'th Nov 2025
Shares of Pacira BioSciences, Inc. (NASDAQ: PCRX - Get Free Report) have earned a consensus recommendation of "Hold" from the seven analysts that are covering the company, MarketBeat reports. One equi
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
08:00am, Tuesday, 11'th Nov 2025
BRISBANE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the liv
DOMA Controls 6.8% of Pacira Common Stock MIAMI , Nov. 10, 2025 /PRNewswire/ -- DOMA Perpetual Capital Management LLC, a significant stockholder of Pacira BioSciences, Inc. (NASDAQ: PCRX) ("Pacira"),
Pacira BioSciences, Inc. (PCRX) Q3 2025 Earnings Call Transcript
06:16am, Friday, 07'th Nov 2025
Pacira BioSciences, Inc. ( PCRX ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Susan Mesco - Head of Investor Relations Frank Lee - CEO & Director Brendan Teehan - Chief Com
Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance
04:01pm, Thursday, 06'th Nov 2025
-- Third quarter revenues up 6% driven by EXPAREL volume growth of 9% -- -- Several key milestones advance 5x30 path to growth and value creation -- -- Conference call today at 4:30 p.m. ET -- BRISBAN
-- Milestone advances two-part study evaluating novel, locally administered gene therapy designed to increase anti-inflammatory IL-1Ra production in the knee joint -- BRISBANE, Calif., Nov. 05, 2025 (
-- Advances 5x30 strategy by expanding pipeline with a highly complementary asset that has the potential to provide several days of pain control -- -- Phase 2 program for AMT-143 expected to begin i
Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025
08:00am, Thursday, 30'th Oct 2025
BRISBANE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the liv
Pacira (PCRX) Expected to Beat Earnings Estimates: Should You Buy?
11:07am, Wednesday, 29'th Oct 2025
Pacira (PCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
